Amneal Pharmaceuticals, Inc. (AMRX) stock
AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3062% above fair value
$21.23−0.15 (-0.70%)
Close on Nov 16, 2026Market cap $6.78BP/E 43.3Yield –
Amneal Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Amneal Pharmaceuticals's price to sales ratio was 2.3× on Nov 11, 2026, against 1.4× a year earlier. Over the last 5 years it ranged from 0.1× to 2.3×, with a median of 0.6×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.3× | +0.9 |
| 2025 | Dec 31, 2025 | 1.4× | +0.5 |
| 2024 | Dec 31, 2024 | 0.9× | +0.5 |
| 2023 | Dec 29, 2023 | 0.4× | +0.3 |
| 2022 | Dec 30, 2022 | 0.1× | −0.2 |
| 2021 | Dec 31, 2021 | 0.3× | −0.0 |
| 2020 | Dec 31, 2020 | 0.4× | −0.0 |
| 2019 | Dec 31, 2019 | 0.4× | −0.2 |
| 2018 | Dec 31, 2018 | 0.6× | – |
See a number that looks wrong?